Company: PRME
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050422
Chunk: 20

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
Item 1. Financial Statements (unaudited)

PRIME MEDICINE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(in thousands, except share and per share amounts)September 30,2025December 31,2024AssetsCurrent assets:Cash and cash equivalents$71,396 $182,476 Short-term investments137,030 2,998 Short-term investment — related party4,861 4,968 Prepaid expenses2,493 6,777 Other current assets15,626 14,667 Total current assets231,406 211,886 Property and equipment, net22,046 24,404 Operating lease right-of-use assets117,869 47,156 Restricted cash13,691 14,062 Total assets$385,012 $297,508 Liabilities and Stockholders’ EquityCurrent liabilities:Accounts payable$9,354 $11,351 Accrued expenses and other current liabilities11,000 15,904 Deferred revenue — related party6,951 7,092 Operating lease liability7,714 3,614 Total current liabilities35,019 37,961 Deferred revenue, net of current — related party59,751 63,218 Operating lease liability, net of current110,421 37,180 Research and development funding liability18,000 6,000 Total liabilities223,191 144,359 Commitments and contingenciesStockholders’ equityCommon stock, par value of $0.00001 per share; 775,000,000 shares authorized; 180,309,471 and 131,160,842 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively2 2 Additional paid-in capital1,004,061 840,358 Accumulated other comprehensive loss33 1 Accumulated deficit(842,275)(687,212)Total stockholders’ equity161,821 153,149 Total liabilities and stockholders’ equity$385,012 $297,508 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

PRIME MEDICINE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

Three Months EndedSeptember 30,Nine Months EndedSeptember 30